Literature DB >> 15172997

Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract.

Nicolas Wentzensen1, Svetlana Vinokurova, Magnus von Knebel Doeberitz.   

Abstract

Cancers of the anogenital tract as well as some head and neck cancers are caused by persistent infections with high-risk type human papillomaviruses (HPVs). Two viral oncogenes, E6 and E7, induce severe chromosomal instability associated with centrosome aberrations, anaphase bridges, chromosome lagging, and breaking. This occurs early in preneoplastic lesions, when the viral genome still persists in an episomal state. In most invasive cancers and also in a few high-grade dysplastic lesions, however, integration of high-risk HPV genomes into the host genome is observed. Integration seems to be a direct consequence of chromosomal instability and an important molecular event in the progression of preneoplastic lesions. Disruption or deregulation of defined critical cellular gene functions by insertional mutagenesis by integrated HPV genome fragments has been hypothesized as one major promoting factor in the pathogenesis of HPV-associated cancers. This hypothesis was based on the detection of HPV integration events in the area of tumor-relevant genes in few cases. Here, we reviewed >190 reported integration loci with respect to changes in the viral structure and the targeted genomic locus. This analysis confirms that HPV integration sites are randomly distributed over the whole genome with a clear predilection for genomic fragile sites. No evidence for targeted disruption or functional alteration of critical cellular genes by the integrated viral sequences could be found.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172997     DOI: 10.1158/0008-5472.CAN-04-0009

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  141 in total

1.  Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer.

Authors:  Clara Bodelon; Svetlana Vinokurova; Joshua N Sampson; Johan A den Boon; Joan L Walker; Mark A Horswill; Keegan Korthauer; Mark Schiffman; Mark E Sherman; Rosemary E Zuna; Jason Mitchell; Xijun Zhang; Joseph F Boland; Anil K Chaturvedi; S Terence Dunn; Michael A Newton; Paul Ahlquist; Sophia S Wang; Nicolas Wentzensen
Journal:  Carcinogenesis       Date:  2015-12-09       Impact factor: 4.944

2.  Correlation between physical status of human papilloma virus and cervical carcinogenesis.

Authors:  Kezhen Li; Xin Jin; Yong Fang; Changyu Wang; Mei Gong; Pingbo Chen; Jia Liu; Dongrui Deng; Jihui Ai
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

Review 3.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

4.  Deletion mapping of chromosome 13q in head and neck squamous cell carcinoma in Indian patients: correlation with prognosis of the tumour.

Authors:  Md Golam Sabbir; Anup Roy; Syamsundar Mandal; Aniruddha Dam; Susanta Roychoudhury; Chinmay Kumar Panda
Journal:  Int J Exp Pathol       Date:  2006-04       Impact factor: 1.925

Review 5.  Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer.

Authors:  Farhoud Faraji; Munfarid Zaidi; Carole Fakhry; Daria A Gaykalova
Journal:  Microbes Infect       Date:  2017-06-12       Impact factor: 2.700

Review 6.  Human Papillomavirus Laboratory Testing: the Changing Paradigm.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

Review 7.  Human papillomavirus DNA methylation as a potential biomarker for cervical cancer.

Authors:  Megan A Clarke; Nicolas Wentzensen; Lisa Mirabello; Arpita Ghosh; Sholom Wacholder; Ariana Harari; Attila Lorincz; Mark Schiffman; Robert D Burk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10-03       Impact factor: 4.254

8.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Authors:  Cornelia L Trimble; Matthew P Morrow; Kimberly A Kraynyak; Xuefei Shen; Michael Dallas; Jian Yan; Lance Edwards; R Lamar Parker; Lynette Denny; Mary Giffear; Ami Shah Brown; Kathleen Marcozzi-Pierce; Divya Shah; Anna M Slager; Albert J Sylvester; Amir Khan; Kate E Broderick; Robert J Juba; Timothy A Herring; Jean Boyer; Jessica Lee; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi
Journal:  Lancet       Date:  2015-09-17       Impact factor: 79.321

9.  Bioluminescent imaging of HPV-positive oral tumor growth and its response to image-guided radiotherapy.

Authors:  Rong Zhong; Matt Pytynia; Charles Pelizzari; Michael Spiotto
Journal:  Cancer Res       Date:  2014-02-13       Impact factor: 12.701

10.  Clinical significance of hTERC gene amplification detection by FISH in the screening of cervical lesions.

Authors:  Yuan Zhang; Xiaobei Wang; Ling Ma; Zehua Wang; Lihua Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.